Personalized medicine/ precision medicine (PM) is considered as the future of healthcare as it offers patients individualized treatment experience with promising clinical benefits. Particularly in oncology where cancer is known as a disease of genome, PM has the potential to provide tailored treatment with the best clinical outcomes. Recent advances in science have led to the development of innovative products that will accelerate the realization of PM. However, some of these technologies pose significant challenges to the existing approach of HTA. Two prime examples of these technologies are Next Generation Sequencing (NGS) or Comprehensive Genomic Profiling (CGP) which can test multiple genes at the same time, and help predict patient responses across multiple targeted therapies in multiple cancer indications, and tumor-agnostic therapies which is informed by genomic alterations regardless of tumor location. Tumor-agnostic therapies such as entrectinib for neutrophic receptor tyrosine kinase gene fusion (NTRK) or pembrolizumab for high microsatellite instability (MSI-H) as well as large panel gene testing like NGS or CGP have been made available in many countries including in the APAC region. However, employing traditional HTA approaches in the assessment of these new technologies may not fully capture their values. Not accounting for heterogeneity of treatment effects across patients and not sufficiently acknowledging elements of personalized medicine may result in restricted and delayed patient access, and may unintentionally set back countries' drive toward personalized medicine.